Is Aphria (TSX:APHA) Stock a Buy After its Potential Merger With Tilray (NASDAQ:TLRY)?

Aphria’s merger with Tilray will result in one of the largest cannabis companies in the world.

| More on:
Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Cannabis stocks have experienced a strong rally since Joe Biden won the presidential race in late 2020. Investors expect the Democrats to decriminalize or even legalize cannabis at the federal level in the U.S., which will generate massive demand for pot products. Further, cannabis companies will also have access to traditional forms of finances.

Shares of Aphria (TSX:APHA)(NASDAQ:APHA) are trading at $10.9 and have gained over 80% since November 2020. Let’s take a look if the Canadian cannabis giant remains a top bet for investors in 2021 as well.

Aphria merges with Tilray

Last month, Aphria announced a merger with Tilray (NASDAQ:TLRY) in an all-stock deal likely to close in the second quarter of 2021. After the merger, the combined entity will generate $874 million in sales, making it the largest Canadian cannabis company.

Aphria and Tilray will not be able to enter the highly lucrative U.S. market unless marijuana is legalized at the federal level. It means they are allowed to sell only hemp-based products south of the border.

The two companies expect to generate $100 million in pre-tax cost savings after the merger. However, similar to most other mergers, Aphria and Tilray will also have to grapple with redundancies and short-term pains associated with mergers.

Another matter of concern is the negative profit margins of both Tilray and Aphria. In the first three quarters of 2020, Tilray’s net loss stood at US$268 million, significantly higher than the US$102 million it lost in the prior-year period.

While Aphria has achieved a positive EBITDA for six consecutive quarters, it has reported a net loss in three of the last four periods. In the last reported quarters, Aphria’s sales fell 4% on a sequential basis while Tilray’s sales were flat year over year.

What’s next for investors?

Aphria investors will own 62% of the combined entity at the end of the merger. Historically, the buyer’s stock price is negatively impacted in the short term after an acquisition or merger takes place. But over the long term, the stock prices gain momentum if the combined entity manages to benefit from cost synergies and produce a diverse business that consistently increases shareholder return.

Tilray is one of the largest producers of hemp and this business generated US$61.5 million in sales in the first nine months of 2020. This suggests hemp sales account for 40% of the company’s top line and was higher than the US$58.5 million it generated via cannabis sales.

Aphria can gain traction in the U.S. hemp market via this merger. Further, the company also acquired Sweetwater Brewing Company for US$300 million in a cash-and-stock deal, allowing it to enter the cannabis beverage segment in the U.S.

The cannabis segment is still at a very nascent stage and investors should brace for further consolidation in this sector. Right now, it seems Aphria’s merger with Tilray will provide the company with enough ammunition to become one of the largest pot players in the world.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »